Section Arrow
Quote
EVAX.NASDAQ
- Evaxion Biotech A/S American Depositary Share
(Financial Status)
Quotes are at least 15-min delayed:2025/01/11 18:01 EST
Last
 0.9
+0.01 (+1.12%)
Day High 
0.93999 
Prev. Close
0.89 
1-M High
1.39 
Volume 
166.05K 
Bid
0.8512
Ask
0.92
Day Low
0.807 
Open
0.9 
1-M Low
0.83 
Market Cap 
5.22M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 0.92 
20-SMA 0.99 
50-SMA 1.57 
52-W High 13.61 
52-W Low 0.83 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.80/0.80
Enterprise Value
15.61M
Balance Sheet
Book Value Per Share
0.01
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
73.00K
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
CDTConduit Pharmaceuticals0.1233+0.0413+50.37%-- 
MRSNMersana Therapeutics0.72-0.58-44.62%-- 
TNXPTonix Pharmaceuticals Holding Corp.0.2787+0.0227+8.87%-- 
ZVSAZyVersa Therapeutics1.47+0.29+24.58%0PE
SANASana Biotechnology3.66-0.64-14.88%-- 
Quotes are at least 15-min delayed：2025/01/11 18:01 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.